Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02176967 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 25, 2026 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

The 50 most recent of 55 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Study sites revised (222)v55 See this version in full on ClinicalTrials.gov ↗
  2. Study sites revised (222)v54 See this version in full on ClinicalTrials.gov ↗
  3. Study sites revised (222)v53 See this version in full on ClinicalTrials.gov ↗
  4. Study sites revised (222)v52 See this version in full on ClinicalTrials.gov ↗
  5. Study sites revised (222)v51 See this version in full on ClinicalTrials.gov ↗
Show 45 earlier versionsHide 45 earlier versions
  1. Re-verified, no change to tracked fieldsv50
  2. Study sites revised (222)v49 See this version in full on ClinicalTrials.gov ↗
  3. Re-verified, no change to tracked fieldsv48
  4. Study sites revised (222)v47 See this version in full on ClinicalTrials.gov ↗
  5. Re-verified, no change to tracked fieldsv46
  6. Study sites revised (222)v45 See this version in full on ClinicalTrials.gov ↗
  7. Re-verified, no change to tracked fieldsv44
  8. Study sites revised (222)v43 See this version in full on ClinicalTrials.gov ↗
  9. Re-verified, no change to tracked fieldsv42
  10. Trial status: Recruiting to Active, Not Recruiting Start date: Jul 28, 2014 to Aug 8, 2014 · Interventions: Carboplatin (Drug), Clinical Observation (Other), Cyclophosphamide (Drug), Doxorubicin Hydrochloride (Drug), Etoposide (Drug), Laboratory… to Biopsy (Procedure), Bone Marrow Aspiration (Procedure), Bone Marrow Biopsy (Procedure), Carboplatin (Drug), Clinical Observation (Other)… · Eligibility criteria revised · 2 morev41 Show 5 more changesShow less
    • Start date: Jul 28, 2014 to Aug 8, 2014
    • Interventions: Carboplatin (Drug), Clinical Observation (Other), Cyclophosphamide (Drug), Doxorubicin Hydrochloride (Drug), Etoposide (Drug), Laboratory… to Biopsy (Procedure), Bone Marrow Aspiration (Procedure), Bone Marrow Biopsy (Procedure), Carboplatin (Drug), Clinical Observation (Other)…
    • Eligibility criteria revised
    • Study description expanded, about 69 words
    • Site details revised at 222 of 222 sites

    See this version in full on ClinicalTrials.gov ↗

  11. Site details revised at 7 of 222 sitesv40
  12. Study sites revised (222)v39 See this version in full on ClinicalTrials.gov ↗
  13. Study sites: 221 to 222v38
  14. Study sites: 220 to 221v37
  15. Site details revised at 2 of 220 sitesv36
  16. Study sites: 219 to 220v35
  17. Site details revised at 11 of 219 sitesv34
  18. Primary and study completion dates: Mar 30, 2026 to Sep 30, 2026 Site details revised at 14 of 219 sitesv33 Show 1 more changeShow less
    • Site details revised at 14 of 219 sites
  19. Study sites revised (219)v32 See this version in full on ClinicalTrials.gov ↗
  20. Primary and study completion dates: Sep 30, 2025 to Mar 30, 2026v31
  21. Site details revised at 11 of 219 sitesv30
  22. Study sites: 218 to 219v29
  23. Site details revised at 12 of 218 sitesv28
  24. Site details revised at 6 of 218 sitesv27
  25. Re-verified, no change to tracked fieldsv26
  26. Study sites: 217 to 218v25
  27. Site details revised at 9 of 217 sitesv24
  28. Study sites revised (217)v23 See this version in full on ClinicalTrials.gov ↗
  29. Study sites: 216 to 217v22
  30. Study sites: 214 to 216v21
  31. Study sites: 213 to 214v20
  32. Site details revised at 2 of 213 sitesv19
  33. Completion date: Sep 30, 2025 Eligibility criteria revised · Study sites revised (213)v18 Show 2 more changesShow less
    • Eligibility criteria revised
    • Study sites revised (213)

    See this version in full on ClinicalTrials.gov ↗

  34. Study sites revised (213)v17 See this version in full on ClinicalTrials.gov ↗
  35. Study sites revised (213)v16 See this version in full on ClinicalTrials.gov ↗
  36. Primary completion date: Jun 30, 2026 to Sep 30, 2025v15
  37. Study sites: 212 to 213v14
  38. Site details revised at 10 of 212 sitesv13
  39. Secondary endpoints shortened, about 81 words Study sites revised (212) · Study description expanded, about 3 wordsv12 Show 2 more changesShow less
    • Study sites revised (212)
    • Study description expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  40. Study sites revised (212)v11 See this version in full on ClinicalTrials.gov ↗
  41. Study sites: 213 to 212v10
  42. Study sites: 211 to 213v9
  43. Primary completion date: Jun 2019 to Jun 30, 2026 Primary endpoints: 2 to 1 · Study sites: 107 to 211 · Start date: Jul 2014 to Jul 28, 2014 · 3 morev8 Show 6 more changesShow less
    • Primary endpoints: 2 to 1
    • Study sites: 107 to 211
    • Start date: Jul 2014 to Jul 28, 2014
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: 9 to 10
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  44. 2 versions Re-verified since Sep 23, 2016, no change to tracked fieldsv6-v7
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk neuroblastoma and may help to avoid some of the risks and side effects related to standard treatment.
Trial Details
NCT Number NCT02176967
Lead Sponsor Children's Oncology Group
Collaborators: National Cancer Institute (NCI)
Conditions Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
Enrollment 621 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov